1 / 52

Tuberculosis control

Tuberculosis control. Dr. Pracheth R. MD, DNB, PGDPHSM . Assistant Professor, Dept. Community Medicine, YMC. Outline. DOTS MDR and XDR TB Childhood TB BCG vaccination TB and HIV RNTCP. Treatment : Anti-TB drugs. Bactericidal: Rifampicin Isoniazid Streptomycin Pyrazinamide.

armandot
Download Presentation

Tuberculosis control

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Tuberculosis control Dr. Pracheth R. MD, DNB, PGDPHSM. Assistant Professor, Dept. Community Medicine, YMC.

  2. Outline • DOTS • MDR and XDR TB • Childhood TB • BCG vaccination • TB and HIV • RNTCP

  3. Treatment : Anti-TB drugs Bactericidal: • Rifampicin • Isoniazid • Streptomycin • Pyrazinamide

  4. Continued….. Bacteriostatic: • Ethambutol • Thioacetazone Second line drugs: • Fluroquinolones • Ethionamide • Capreomycin • Kanamicin, amikacin • Cycloserine

  5. DOTS

  6. DIRECTLY OBSERVED TREATMENT, SHORT COURSE (DOTS) CHEMOTHERAPY • Intensive phase- trained worker watches, patient swallows drug in his presence • Continuation phase- medicines for 1 week in a multiblistercombipack, first dose swallowed in presence of health worker

  7. Daily regimen • In 2013: National Expert Committee • Will be implemented shortly • Category 1: • IP: 2HRZE, CP: 4HR • Category 2: • IP: 2HRZES+1HRZE, CP: 5HRE

  8. MDR TB • Resistant: isoniazid, rifampicin • XDR TB: • almost all second line drugs • Rifampicin and Isoniazid • Fluroquinolone • One of: amikacin, capreomycin, kanamycin

  9. Types and causes • Primary or pre-treatment: • Not received drug before-episomes • Secondary or acquired: • Initially sensitive • Incorrect prescription • Irregular supply drugs • Non-compliance • Lack of supervision, follow-up

  10. DOTS-Plus- MDR TB (Cat IV)

  11. XDR TB treatment

  12. Childhood TB

  13. Continued… • Around 6-8% all cases: < 15 years • Commonest age: 1-4 years • Source: adult • No. infectious cases • Closeness of contact • Age of child • Rarely: smear positive

  14. Continued… • Severe disease, intolerance: hospitalize • Daily treatment • Discharge: thrice weekly • Doses: as per kg body weight • Patient wise boxes (6)-weight • INH Prophylaxis (10mg/kg): 6 months

  15. INH Prophylaxis • Asymptomatic contacts (<5 years)- smear positive • HIV infected children: exposed-TB case/ Tuberculin positive • Mother: TB pregnancy

  16. TB in pregnancy

  17. Continued….. • HRE: 2 months • HR: 7 months • Stop E after 1 month if H,R sensitive • Z: only resistance • S: contraindicated

  18. MDR-TB in pregnancy

  19. BCG vaccination • Calmette and Guerin : 1906 began attenuating avirulent strain of M. bovis • Repeated subcultures, 13 years: BCG • Initial- oral: 1921-1925 • 1927: first injected intradermally • 1948: well accepted

  20. Continued….. • Aim: • Benign, artificial primary infection • Reduce morbidity and mortality • Vaccine: • Live bacterial vaccine • Danish 1331 strain • Type of vaccine: • Freeze dried and liquid (fresh)

  21. Continued….. • Stable-: refrigerated below 10 degree C • Normal Saline- reconstituent • Reconstituted vaccine- used within 3 hours, left over vaccine- discarded • Dosage: • Newborn <4 weeks: 0.05 ml; >4 weeks: 0.1 ml • Thin skin

  22. Continued… • Administration: • Intradermal ; Tuberculin syringe • Subcutaneously- abscess • Just above insertion of deltoid • Satisfactory injection: wheal-5cm.

  23. Continued… • Phenomena after vaccination: • 2-3 weeks: papule • Increases in size-4 to 8 mm-5 weeks • Breaks –ulcer-covered with a crust • Spontaneous healing: 6-12 weeks- scar:4-8mm • Mantoux +: 8 weeks

  24. Continued… • Complications: • Severe ulceration • Suppurative lymphadenitis • Osteomyelitis • Disseminated BCG infection

  25. Continued.. • Local abscess: • Aspiration • Incised, daily local applications-INH/ PAS powder • Assure patient • Avoid vaccination in same arm for 6 months

  26. Continued… • Protective value: • For 15-20 years • Immunity response-delayed hypersensitivity • Range of protection: 0-80% • Partial protection

  27. Continued… • Contraindications: • Generalized eczema • Infective dermatosis • History of deficient immunity (symptomatic HIV infection, congenital immunodeficiency leukaemia, lymphoma) • Immunosuppressive treatment • Pregnancy

  28. Continued… • Direct BCG vaccination: • Without prior tuberculin test • Administer before contact : environmental mycobacteria

  29. TB+ HIV

  30. Continued… • HIV damages immunity • Reactivate latent infection • Primary infection-progresses faster • Recurring infection • Community

  31. Diagnosis- TB in HIV • High negative smears • Tuberculin test may fail • Chest X-ray: less cavitation • More extra-pulmonary TB • Screen all HIV +: sputum smear • Negative: culture • Culture not done: X-ray +clinical symptoms

  32. Diagnose HIV in TB patients • High prevalence: HIV test all TB patients • Pre-test , post-test counseling • Integrated Counseling and Testing Centre • High-risk behaviour

  33. ART to patients with MDR-TB

  34. TB and diabetes • Risk factor for TB • Around 15% of all TB cases • Weak immune system • All TB cases-screen: diabetes • High TB prevalence: all diabetes-TB screening • Death during treatment, relapse

  35. RNTCP • NTP: 1962 • Inadequate funds • Over-reliance X-ray • Interrupted drug supply • Low rates: completion • In 1993: RNTCP • Pilot phase: 1998- 2% of country • By 2006: whole country

  36. Objectives and components 1. Cure rate : 85% 2. Case detection: 70% • Political will • Diagnosis: quality assured sputum microscopy • Adequate supply of drugs • Directly observed treatment • Systematic monitoring, accountability

  37. New initiatives • Nucleic Acid Amplification Test- GeneXpert • Nikshay: web based application • Mandatory TB notification • Ban on TB serology : • Remote infection • Poor specificity

  38. Future • Case-finding, treatment: major disease • Bacilli capable: living body-years • Drug-resistant strains • TB+HIV • Social factors

  39. Questions • Advantages of DOTS therapy (3 marks) • Defaulters in TB treatment (3 marks) • Define TB control. Explain it in detail (1+5=6 marks) • Explain early detection of tuberculosis (6 marks) • Define new case, relapse, failure with reference to TB (3 marks) • Explain briefly Mantoux Test (3 marks)

  40. Questions 7. Enumerate the cardinal features of TB (2 marks) 8. What is supervised treatment in TB ( 2 marks) 9. Components of DOTS ( 3 marks) 10. Define MDR and XDR TB ( 3 marks) 11. DOTS-Plus strategy (3 marks).

More Related